Immuneering Corporation (IMRX)
Automate Your Wheel Strategy on IMRX
With Tiblio's Option Bot, you can configure your own wheel strategy including IMRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMRX
- Rev/Share 0.0
- Book/Share 1.1777
- PB 2.0718
- Debt/Equity 0.0976
- CurrentRatio 7.4796
- ROIC -1.3986
- MktCap 87805108.0
- FreeCF/Share -1.5099
- PFCF -1.6368
- PE -1.4034
- Debt/Assets 0.0806
- DivYield 0
- ROE -1.1922
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IMRX | Morgan Stanley | Equal Weight | Underweight | -- | -- | Dec. 13, 2024 |
News
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer.
Read More
About Immuneering Corporation (IMRX)
- IPO Date 2021-07-30
- Website https://immuneering.com
- Industry Biotechnology
- CEO Dr. Benjamin J. Zeskind M.B.A., Ph.D.
- Employees 54